Activity testing is in progress. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first.

BCMA/TNFRSF17 Protein, Human, Recombinant, AF488-Labeled is expressed in HEK293 Cells. The accession number is Q02223-1.

Human

HEK293 Cells

TNFRSF13A,CD269,BCMA,BCM

A DNA sequence encoding the extracellular domain (Met1-Ala54) of human TNFRSF17 (NP_001183.2) was expressed with a C-terminal polyhistidine tag. The protein is site-specifically conjugated with AF 488 (Excitation Max.= 495 nm, Emission Max.= 519 nm).

≥ 90% as determined by SDS-PAGE.

Please refer to the lot-specific COA.

Twelve months from date of receipt at -20℃ to -70℃ in lyophilized form and 3 months at -70℃ under sterile conditions after reconstitution. Protect from prolonged exposure to light and avoid repeated freeze-thaw cycles.

Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13BBAFF), and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.